EasySep? Mouse Na?ve CD4+ T Cell Isolation Kit
Immunomagnetic negative isolation of untouched mouse na?ve CD4+ T cells
Before performing cell isolation using EasySep?, consult the product information sheet (PIS) to determine whether red blood cell (RBC) lysis is required for your sample type. RBC lysis should only be performed if indicated in the PIS. It is often recommended for blood samples; however, RBC lysis is not recommended for mouse splenocytes as it may reduce cell recovery. For the most accurate cell recovery calculation, we recommend performing total nucleated cell (TNC) count.
See How to Calculate Cell Recovery & Measure Purity After Cell Isolation >
See How to Calculate Cell Recovery & Measure Purity After Cell Isolation >
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to 海角破解版 Technologies Canada Inc. and its subsidiaries and affiliates (“海角破解版”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the ?and??apply.
This site is protected by reCAPTCHA and the ?and??apply.
Products for Your Protocol
To see all required products for your protocol, please consult the
Protocols and Documentation.
- EasySep? Magnet
Magnet for column-free immunomagnetic separation
- EasySep? Buffer
Cell separation buffer for use with EasySep? cell separation kits
Overview
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (12)
Frequently Asked Questions
Publications (23)
Regulatory T-cell sensing of extracellular ATP via P2RX7 promotes their accumulation and suppression and drives lung tumor growth
Cancer immunology research 2026 Jan
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide and, despite advances in treatment, immune suppression remains an obstacle to effective therapy. Effector CD4+ T cells (CD4+ Teffs) are critical for antitumor immunity, but their function is often inhibited by regulatory T cells (Tregs), which accumulate in lung tumors and mediate suppressive functions through multiple mechanisms. This suppression leads to tumor progression and poor patient outcomes. However, the mechanisms underlying Treg-mediated suppression are not fully understood. Herein, we identify the extracellular ATP receptor P2RX7 as a key regulator of Treg function in lung tumors. In a murine lung cancer model induced by Lewis lung carcinoma cells, we found that P2RX7 enhanced the suppressive capacity of tumor-infiltrating Tregs, promoting tumor growth. In T cell–specific P2RX7-KO mice, reduced Treg infiltration was accompanied by increased CD4+ Teff accumulation and improved tumor control. Treg-specific P2RX7-KO mice exhibited reduced tumor growth, confirming a Treg-intrinsic role of P2RX7. Suppression assays revealed that tumor-infiltrating wild-type Tregs had greater suppressive activity compared to P2RX7-KO Tregs, which failed to inhibit type 1 and Tfh-like responses. This was associated with increased tumor-specific IgG production by lung B cells in P2RX7-KO mice. We also observed that wild-type Tregs expressed higher levels of the immunosuppressive molecule CTLA-4 when compared to P2RX7-KO Tregs. Thus, we conclude that P2RX7 expression on Tregs is essential for their suppressive function in lung cancer and targeting of P2RX7 may constitute a strategy to improve lung cancer treatment by alleviating Treg-mediated immune suppression.
Bacterial vesicles from intratumoral L. salivarius enhance PD-1 blockade via FPR1-mediated macrophage polarization in gastric cancer
Cell Reports Medicine 2026 Feb
Abstract
The immunomodulatory function of the gastric microbiota in cancer is poorly understood, partly due to the stomach’s acidic environment and limited microbial colonization. Here, by analyzing 68 paired human gastric cancer (GC) samples, we identify Ligilactobacillus salivarius as a commensal bacterium depleted in tumors but enriched in immune checkpoint blockade (ICB) responders. Oral administration of L. salivarius enhances anti-PD-1 efficacy in multiple GC mouse models by promoting pro-inflammatory macrophage activation. Mechanistically, bacterial extracellular vesicles (bEVs) derived from L. salivarius deliver 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (2,3-BdpM) to tumors, where it activates formyl peptide receptor 1 (FPR1) on macrophages, triggering mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB) signaling. Moreover, 2,3-BdpM augments the cytotoxic activity of chimeric antigen receptor (CAR)-Claudin18.2+ macrophages in an FPR1-dependent manner. These findings describe a microbial-macrophage axis that enhances GC immunotherapy and highlights the translational potential of orally deliverable microbial adjuvants. Graphical abstract Highlights?Intratumoral reduction of L. salivarius correlates with GC immunotherapy efficacy?bEVs derived from L. salivarius enhance immunotherapy efficacy in GC mouse models?2,3-BdpM in bEV triggers pro-inflammatory macrophage remodeling via FPR1?The cytotoxicity of CAR-Claudin18.2+ macrophages was amplified with 2,3-BdpM alone Yu et al. identify Ligilactobacillus salivarius as a gastric commensal enriched in immunotherapy responders. Oral administration enhances anti-PD-1 efficacy by delivering 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (2,3-BdpM) via bacterial extracellular vesicles (bEVs) to activate pro-inflammatory macrophages through formyl peptide receptor 1 (FPR1), revealing a microbial-macrophage axis that potentiates gastric cancer immunotherapy.
Conditioned medium from stem cells of human exfoliated deciduous teeth ameliorates mouse ovalbumin-specific allergic dermatitis
Stem Cell Research & Therapy 2025 Oct
Abstract
BackgroundAtopic dermatitis (AD), a chronic inflammatory skin disease, is characterized by intense itching and recurrent eczema-like lesions, requiring safer, more targeted therapies that modulate the immune response and restore skin barrier integrity. Conditioned medium derived from stem cells of human exfoliated deciduous teeth (SHED-CM) exhibits considerable immunomodulatory and regenerative effects. We evaluated the efficacy of SHED-CM in an AD-like mouse model and explored the underlying mechanisms.MethodsMice with ovalbumin (OVA)-specific allergic dermatitis (OSAD) were intravenously treated with SHED-CM, conditioned medium derived from fibroblast, or Dulbecco’s Modified Eagle Medium, followed by antigen restimulation to induce AD-like dermatitis. Disease severity was assessed macroscopically and histologically. T cell phenotypes were analyzed using immunohistochemical staining, RT-qPCR, and flow cytometry. Total serum and OVA-specific immunoglobulin E (IgE) levels were measured using ELISA. Na?ve splenic CD4? T cells were activated using CD3/CD28 beads in SHED-CM to evaluate their direct effects on T cell differentiation through flow cytometry. Highly expressed proteins in SHED-CM were identified using liquid chromatography–mass spectrometry, and neutralizing antibodies were used to elucidate the therapeutic mechanisms.ResultsThe treatment with SHED-CM significantly ameliorated AD-like symptoms, reduced epidermal hyperplasia, and restored filaggrin expression. SHED-CM created an anti-inflammatory microenvironment in OSAD skin and draining lymph nodes by promoting Treg differentiation and inhibiting Th2 and Th17 populations. SHED-CM markedly suppressed B cell maturation, antigen-specific IgE production, and mast cell activation. Furthermore, we found that SHED-CM directly promoted Treg differentiation from na?ve CD4? T cells stimulated by CD3/CD28, which was mediated, in part, through TGFβ contained in SHED-CM. SHED-CM exhibited little to no effect on in vitro Th1, Th2, and Th17 differentiation.ConclusionsSHED-CM shows significant therapeutic potential for AD-like symptom, effectively modulating immune response and enhancing skin barrier restoration. Our findings offer a new approach for developing novel, targeted therapies for inflammatory skin disorders.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13287-025-04735-2.
Before performing cell isolation using EasySep?, consult the product information sheet (PIS) to determine whether red blood cell (RBC) lysis is required for your sample type. RBC lysis should only be performed if indicated in the PIS. It is often recommended for blood samples; however, RBC lysis is not recommended for mouse splenocytes as it may reduce cell recovery. For the most accurate cell recovery calculation, we recommend performing total nucleated cell (TNC) count.
See How to Calculate Cell Recovery & Measure Purity After Cell Isolation >
See How to Calculate Cell Recovery & Measure Purity After Cell Isolation >
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT 海角破解版, REFER TO WWW.海角破解版.COM/COMPLIANCE.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT 海角破解版, REFER TO WWW.海角破解版.COM/COMPLIANCE.
